IDEXX Laboratories, Inc. vs Quantum Computing Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Quantum Computing Inc trades at $7.46 (market cap $1.69B). The key difference: IDEXX Laboratories, Inc. is far larger — about 23.9× Quantum Computing Inc's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 7,991,522). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Quantum Computing Inc for 25 Days on average.
| IDXX | QUBT | |
|---|---|---|
Market Cap | $40.43B | $1.69B |
Volume | 692,164 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $766.68 | $21.78 |
52-Week Low | $504.70 | $6.31 |
Typical Hold Time | 46 Days | 25 Days |
Enterprise Value | $41.32B | $753.24M |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Quantum Computing Inc. (QUBT) trades at $7.43, down 2.49% today, with a bearish technical signal despite bullish oscillators. The company shows explosive revenue growth from $682K in 2025 to $10M projected for 2026, but remains deeply unprofitable with a -152.45% net income margin. Recent developments include the Dirac-3S quantum system launch and a $42.5M backlog, though rising expenses and shareholder litigation create headwinds.
QUBT offers speculative growth potential in quantum computing with strong analyst support (75% buy rating, $17.33 target) but faces significant execution risks. The stock's appeal hinges on commercializing quantum technology amid persistent losses and competitive threats, requiring careful risk assessment by growth-oriented investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →